Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-guided early withdrawal of immunosuppression after allogeneic stem cell transplantation in acute myeloid leukemia
NL-OMON38951Phase 2Suspended
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2013
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mycophenolate mofetil and cyclosporine in acute myeloid leukemia (AML), sponsored by Amsterdam University Medical Center. Primary endpoint: Cumulative incidence of hematological relapse. Started Apr 2013; status: suspended.
02
Drugs
mycophenolate mofetilcyclosporine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON38951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38951.